Literature DB >> 32266314

Sweet's Syndrome as Manifestation of Active Ulcerative Colitis.

Mario Bento-Miranda1, David N Perdigoto1, Sofia Mendes1, Francisco Portela1.   

Abstract

Entities:  

Keywords:  Extraintestinal manifestations; Golimumab; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Year:  2019        PMID： 32266314      PMCID： PMC7113595          DOI： 10.1159/000501399

Source DB:  PubMed          Journal:  GE Port J Gastroenterol        ISSN： 2387-1954


× No keyword cloud information.
  4 in total

1.  AN ACUTE FEBRILE NEUTROPHILIC DERMATOSIS.

Authors:  R D SWEET
Journal:  Br J Dermatol       Date:  1964 Aug-Sep       Impact factor: 9.302

Review 2.  Disease-related and drug-induced skin manifestations in inflammatory bowel disease.

Authors:  Pieter Hindryckx; Gregor Novak; Antonio Costanzo; Silvio Danese
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2017-02-01       Impact factor: 3.869

Review 3.  Sweet's syndrome: diagnostic criteria revisited.

Authors:  Ahmad Nofal; Ayman Abdelmaksoud; Hala Amer; Eman Nofal; Ayman Yosef; Khaled Gharib; Waleed Albalat; Fatma Eldesouky; Howyda M Ebrahim; Ahmed Said Abdelshafy; Hala Fayed
Journal:  J Dtsch Dermatol Ges       Date:  2017-10-05       Impact factor: 5.584

4.  Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.

Authors:  George Philip; Freddy Cornillie; J Omoniyi Adedokun; Richard Melsheimer; Paul Rutgeerts; Jean-Frédéric Colombel; Colleen Marano
Journal:  J Crohns Colitis       Date:  2019-09-27       Impact factor: 9.071
  4 in total
  1 in total

1.  Systematic Review: Sweet Syndrome Associated with Inflammatory Bowel Disease.

Authors:  Joseph Sleiman; Asif A Hitawala; Benjamin Cohen; Katie Falloon; Marian Simonson; Benjamin Click; Urmi Khanna; Anthony P Fernandez; Florian Rieder
Journal:  J Crohns Colitis       Date:  2021-11-08       Impact factor: 9.071
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.